Pharmacokinetic Profile and Acute Toxicological Properties of a Novel Radiosensitizer Cytosine–Phosphate–Guanosine Oligodeoxynucleotide 107 in Mice Following Intravenous and Orthotopic Administration
Restricted accessResearch articleFirst published online October, 2015
Pharmacokinetic Profile and Acute Toxicological Properties of a Novel Radiosensitizer Cytosine–Phosphate–Guanosine Oligodeoxynucleotide 107 in Mice Following Intravenous and Orthotopic Administration
The synthetic cytosine–phosphate–guanosine oligodeoxynucleotide 107 (CpG ODN107) is a novel radiosensitizer for glioma treatment. However, the information related to its pharmacokinetics and toxicity remains unclear. Therefore, the plasma pharmacokinetics, distribution, elimination, and acute toxicity of CpG ODN107 in mice were investigated in the present experiments. The results from the liquid chromatography–tandem mass spectrometry (LC-MS/MS) assay showed that the plasma elimination half-life (t1/2β) of CpG ODN107 in BALB/c mice varied slightly with the dose, and it was 0.65, 0.49, and 0.50 h at the intravenous doses of 2.5, 5, and 10 mg/kg, respectively. CpG ODN107 rapidly and widely distributed in organs/tissues, except the brain and testes. The highest concentrations were found in the liver (28.6% of the administered dose after 0.5 h) and the kidneys (5.7% of the administered dose after 1 h). CpG ODN107 (0.3, 3, and 30 μg/mL) could highly bind to human and mouse plasma proteins in vitro. CpG ODN107 in the forms of prototype was excreted in urine (1.79%) and feces (0.91%), and its shortened metabolites were excreted in urine (2.1%) and feces (2.2%) within the first 24 h. The mice in vivo optical image showed CpG ODN107 labeled with Alexa Fluor 680 fluorochrome (AF680) accumulated in the brain after orthotopic injection, eliminated very slowly, and excreted in urine compared with poly T labeled with AF680. The median lethal dose (LD50) of CpG ODN107 was 75.7 mg/kg for mice; this dose only could produce apparent spleen and liver damage, in line with the distribution features of CpG ODN. In conclusion, our present pharmacokinetic and toxicity investigation will provide helpful information to further pharmacodynamic and pharmacokinetic research of CpG ODN107 and other oligodeoxynucleotide drugs in the future.
Get full access to this article
View all access options for this article.
References
1.
Abdel-HamidSM, Abdel-HadySE, El-ShamyAA and El-DessoukyHF. (2006). Formulation of an antispasmodic drug as a topical local anesthetic. Int J Pharm, 326:107–118.
2.
GekelerV, GimmnichP, HofmannHP, GrebeC, RommeleM, LejaA, BaudlerM, BenimetskayaL, et al. (2006). G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice. Oligonucleotides, 16:83–93.
3.
CerkovnikP, Jezersek NovakovicB, StegelV and NovakovicS. (2009). Class C CpG oligodeoxynucleotides as a single agent and in combination with radiotherapy efficiently delayed growth of subcutaneous B16F1 tumors. Innate Immun, 15:313–321.
4.
MilasL, MasonKA, ArigaH, HunterN, NealR, ValdecanasD, KriegAM and WhisnantJK. (2004). CpG oligodeoxynucleotide enhances tumor response to radiation. Cancer Res, 64:5074–5077.
5.
MengY, CarpentierAF, ChenL, BoisserieG, SimonJM, MazeronJJ and DelattreJY. (2005). Successful combination of local CpG-ODN and radiotherapy in malignant glioma. Int J Cancer, 116:992–997.
6.
JahrsdorferB and WeinerGJ. (2008). CpG oligodeoxynucleotides as immunotherapy in cancer. Update Cancer Ther, 3:27–32.
7.
ZhaL, QiaoT, YuanS and LeiL. (2010). Enhancement of radiosensitivity by CpG-oligodeoxyribonucleotide-7909 in human non-small cell lung cancer A549 cells. Cancer Biother Radiopharm, 25:165–170.
KahanBD, StepkowskiS, KilicM, KatzSM, Van BurenCT, WelshMS, TamiJA and ShanahanWRJr. (2004). Phase I and phase II safety and efficacy trial of intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302) for the prevention of acute allograft rejection. Transplantation, 78:858–863.
10.
MuradYM and ClayTM. (2009). CpG oligodeoxynucleotides as TLR9 agonists: therapeutic applications in cancer. BioDrugs, 23:361–375.
11.
VollmerJ and KriegAM. (2009). Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv Drug Deliv Rev, 61:195–204.
12.
KriegAM. (2012). CpG still rocks! Update on an accidental drug. Nucleic Acid Ther, 22:77–89.
13.
WasanEK, WaterhouseD, SivakO, BallyMB, KlasaRJ and WasanKM. (2002). Plasma protein binding, lipoprotein distribution and uptake of free and lipid-associated BCL-2 antisense oligodeoxynucleotides (G3139) in human melanoma cells. Int J Pharm, 241:57–64.
14.
BaekMS, YuRZ, GausH, GrundyJS and GearyRS. (2010). In vitro metabolic stabilities and metabolism of 2′-O-(methoxyethyl) partially modified phosphorothioate antisense oligonucleotides in preincubated rat or human whole liver homogenates. Oligonucleotides, 20:309–316.
15.
BroaddusWC, PrabhuSS, GilliesGT, NealJ, ConradWS, ChenZJ, FillmoreH and YoungHF. (1998). Distribution and stability of antisense phosphorothioate oligonucleotides in rodent brain following direct intraparenchymal controlled-rate infusion. J Neurosurg, 88:734–742.
16.
IversenPL, CoppleBL and TewaryHK. (1995). Pharmacology and toxicology of phosphorothioate oligonucleotides in the mouse, rat, monkey and man. Toxicol Lett, 82–83:425–430.
17.
TemplinMV, LevinAA, GrahamMJ, AbergPM, AxelssonBI, ButlerM, GearyRS and BennettCF. (2000). Pharmacokinetic and toxicity profile of a phosphorothioate oligonucleotide following inhalation delivery to lung in mice. Antisense Nucleic Acid Drug Dev, 10:359–368.
18.
CossumPA, TruongL, OwensSR, MarkhamPM, SheaJP and CrookeST. (1994). Pharmacokinetics of a 14C-labeled phosphorothioate oligonucleotide, ISIS 2105, after intradermal administration to rats. J Pharmacol Exp Ther, 269:89–94.
19.
PhillipsJA, CraigSJ, BayleyD, ChristianRA, GearyR and NicklinPL. (1997). Pharmacokinetics, metabolism, and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration. Biochem Pharmacol, 54:657–668.
20.
ChenHX, MarshallJL, NessE, MartinRR, DvorchikB, RizviN, MarquisJ, McKinlayM, et al. (2000). A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors. Clin Cancer Res, 6:1259–1266.
21.
ManiS, RudinCM, KunkelK, HolmlundJT, GearyRS, KindlerHL, DorrFA and RatainMJ. (2002). Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer. Clin Cancer Res, 8:1042–1048.
22.
LiuG, KolesarJ, McNeelDG, LeithC, SchellK, EickhoffJ, LeeF, TraynorA, et al. (2008). A phase I pharmacokinetic and pharmacodynamic correlative study of the antisense Bcl-2 oligonucleotide g3139, in combination with carboplatin and paclitaxel, in patients with advanced solid tumors. Clin Cancer Res, 14:2732–2739.
23.
AgrawalS, ZhangX, LuZ, ZhaoH, TamburinJM, YanJ, CaiH, DiasioRB, et al. (1995). Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration. Biochem Pharmacol, 50:571–576.
24.
LiX, LiuD, LiuX, JiangW, ZhouW, YanW, CenY, LiB, et al. (2012). CpG ODN107 potentiates radiosensitivity of human glioma cells via TLR9-mediated NF-kappaB activation and NO production. Tumour Biol, 33:1607–1618.
25.
LiuD, CaoG, CenY, LiuT, PengW, SunJ, LiX and ZhouH. (2013). The radiosensitizing effect of CpG ODN107 on human glioma cells is tightly related to its antiangiogenic activity via suppression of HIF-1alpha/VEGF pathway. Int Immunopharmacol, 17:237–244.
26.
CenY, LiX, LiuD, PanF, CaiY, LiB, PengW, WuC, et al. (2012). Development and validation of LC-MS/MS method for the detection and quantification of CpG oligonucleotides 107 (CpG ODN107) and its metabolites in mice plasma. J Pharm Biomed Anal, 70:447–455.
27.
DaiG, WeiX, LiuZ, LiuS, MarcucciG and ChanKK. (2005). Characterization and quantification of Bcl-2 antisense G3139 and metabolites in plasma and urine by ion-pair reversed phase HPLC coupled with electrospray ion-trap mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci, 825:201–213.
28.
DengP, ChenX, ZhangG and ZhongD. (2010). Bioanalysis of an oligonucleotide and its metabolites by liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal, 52:571–579.
29.
ZhangW, LeighlN, ZawiszaD, MooreMJ and ChenEX. (2005). Determination of GTI-2040, a novel antisense oligonucleotide, in human plasma by using HPLC combined with solid phase and liquid-liquid extractions. J Chromatogr B Analyt Technol Biomed Life Sci, 829:45–49.
30.
ThienpontLM, Van LanduytKG, StocklD, SaeyensW, De KeukeleireD and De LeenheerAP. (1995). Evaluation of 2-iminoimidazolidin-4-one and thymine as respective internal standards for normal-phase and reversed-phase high-performance liquid chromatographic determination of creatinine in human serum. J Chromatogr B Biomed Appl, 665:63–69.
31.
RaynaudFI, OrrRM, GoddardPM, LaceyHA, LancashireH, JudsonIR, BeckT, BryanB, et al. (1997). Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice. J Pharmacol Exp Ther, 281:420–427.
32.
GearyRS, LeedsJM, HenrySP, MonteithDK and LevinAA. (1997). Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides. Anticancer Drug Des, 12:383–393.
33.
WatanabeTA, GearyRS and LevinAA. (2006). Plasma protein binding of an antisense oligonucleotide targeting human ICAM-1 (ISIS 2302). Oligonucleotides, 16:169–180.
34.
AgrawalS, ZhangX, CaiQ, KandimallaER, ManningA, JiangZ, MarcelT and ZhangR. (1998). Effect of aspirin on protein binding and tissue disposition of oligonucleotide phosphorothioate in rats. J Drug Target, 5:303–312.
35.
GearyRS, BradleyJD, WatanabeT, KwonY, WedelM, van LierJJ and VanVlietAA. (2006). Lack of pharmacokinetic interaction for ISIS 113715, a 2′-0-methoxyethyl modified antisense oligonucleotide targeting protein tyrosine phosphatase 1B messenger RNA, with oral antidiabetic compounds metformin, glipizide or rosiglitazone. Clin Pharmacokinet, 45:789–801.
36.
YuRZ, GearyRS, FlaimJD, RileyGC, TribbleDL, vanVlietAA and WedelMK. (2009). Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2′-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe. Clin Pharmacokinet, 48:39–50.
37.
LendvaiG, VelikyanI, BergstromM, EstradaS, LaryeaD, ValilaM, SalomakiS, LangstromB, et al. (2005). Biodistribution of 68Ga-labelled phosphodiester, phosphorothioate, and 2′-O-methyl phosphodiester oligonucleotides in normal rats. Eur J Pharm Sci, 26:26–38.
38.
NollBO, McCluskieMJ, SniatalaT, LohnerA, YuillS, KriegAM, SchetterC, DavisHL, et al. (2005). Biodistribution and metabolism of immunostimulatory oligodeoxynucleotide CPG 7909 in mouse and rat tissues following subcutaneous administration. Biochem Pharmacol, 69:981–991.
39.
LendvaiG, VelikyanI and BergstromM. (2005). Biodistribution of 68Ga-labelled phosphodiester, phosphorothioate, and 2′-O-methyl phosphodiester oligonucleotides in normal rats. Eur J Pharm Sci, 26:26–38.
40.
CarpentierAF, XieJ, MokhtariK and DelattreJY. (2000). Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs. Clin Cancer Res, 6:2469–2473.
41.
LinZJ, LiW and DaiG. (2007). Application of LC-MS for quantitative analysis and metabolite identification of therapeutic oligonucleotides. J Pharm Biomed Anal, 44:330–341.
42.
YuRZ, KimTW, HongA, WatanabeTA, GausHJ and GearyRS. (2007). Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. Drug Metab Dispos, 35:460–468.
43.
TanakaY, MizokamiM, OritoE, OhbaK, KatoT, KondoY, MboudjekaI, ZekengL, et al. (1998). African origin of GB virus C/hepatitis G virus. FEBS Lett, 423:143–148.
44.
YanL, XuG, QiaoT, ChenW, YuanS and LiX. (2013). CpG-ODN 7909 increases radiation sensitivity of radiation-resistant human lung adenocarcinoma cell line by overexpression of Toll-like receptor 9. Cancer Biother Radiopharm, 28:559–564.
